Who
James Arthur Bristol
Director
Company insider
Files Form 4 as: Director, Ernexa Therapeutics; Director, Erasca; Director, Deciphera Pharmaceuticals.
In numbers
- Trades disclosed
- 109
- Buys
- 1
- Sells
- 16
- Bought
- $83K
- Sold
- $9.1M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 2 Oct 2017
- Last trade
- 31 Aug 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 1 Sep 2026 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,320 at $0.00 | filing |
| 31 Aug 2026filed 1 Sep 2026 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,083 at $0.00 | filing |
| 31 Aug 2026filed 1 Sep 2026 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,320 at $0.00 | filing |
| 31 Aug 2026filed 1 Sep 2026 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,083 at $0.00 | filing |
| 26 Jun 2026filed 29 Jun 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,888 at $0.00 | filing |
| 26 Jun 2026filed 29 Jun 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,888 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,762 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,762 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 7 Feb 2025filed 10 Feb 2025 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —72,074 at $0.00 | filing |
| 1 Jan 2025filed 2 Jan 2025 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,678 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —22,150 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —67,494 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —12,000 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —9,570 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —18,500 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 26 Apr 2024filed 29 Apr 2024 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —124,525 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,747 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.